News | Stents Bifurcation | September 21, 2022

Medtronic Receives FDA Indication for Bifurcation Percutaneous Coronary Intervention with a Drug-eluting Stent

Medtronic is the first and only company to receive FDA indication for bifurcation percutaneous coronary intervention with a drug-eluting stent 

 


September 21, 2022 — Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the provisional bifurcation stenting technique (using a single stent to treat the bifurcation) with the Onyx Frontier drug-eluting stent (DES) and the Resolute Onyx DES.1 This indication will allow Medtronic to provide a robust portfolio of medical education and procedural training for physicians performing percutaneous coronary interventions (PCIs) in patients with bifurcation lesions.  

Bifurcation lesions occur when plaque builds up around the junction of two coronary arteries - where one branches off another. These lesions are considered challenging to treat because of anatomical variations in the vessels and the difficulty associated with reaching the side branches. The treatment of bifurcation lesions is commonly associated with lower success rates and increased rates of long-term adverse cardiac events,2 and since patients with bifurcation lesions often present unique challenges for interventional cardiologists, stent attributes – like those found in the Onyx Frontier and Resolute Onyx drug-eluting products - become important to optimize the treatment of these lesions. 

“The bifurcation expanded indication is yet another exciting milestone for our Coronary business this year,” said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, which is part of the Cardiovascular Portfolio at Medtronic. “As the first and only medical device company to offer this indication to U.S. interventional cardiologists, Medtronic remains committed to investing in DES technology, clinical evidence, and physician education. We are looking forward to helping even more physicians access the tools they need to give their patients best-in-class care.”   

Medtronic is the only company to offer drug-eluting stents featuring a single-wire design – a manufacturing process in which a single strand of wire is formed into a sinusoidal wave to construct a stent.  This design allows for the optimized treatment of complex bifurcation anatomy by providing excellent vessel conformability, easier side branch access, and the option to open the stent cell while maintaining consistent stent scaffolding.2,3 In addition to an ideal stent design, Onyx Frontier and Resolute Onyx DESs are backed by clinical evidence from the Resolute Onyx Bifurcation Study.  Resolute Onyx DES demonstrated low event rates, beating the performance goal for the primary endpoint of target vessel failure at one year.4 The positive results from this study support the safety and efficacy of Resolute Onyx DES and Onyx Frontier DES in non-left main bifurcation lesions using the provisional stenting technique. 

Both the Onyx Frontier and Resolute Onyx DESs are FDA and CE Mark approved. 

For more information: www.medtronic.com 


Related Content

News | Stents

July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and ...

Home July 05, 2022
Home
News | Stents

June 2, 2022 — According to the U.S. Food and Drug Administration (FDA), Atrium Medical Corporation is recalling the ...

Home June 02, 2022
Home
News | Stents

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

Home May 13, 2022
Home
News | Stents

April 6, 2022 – Narrowed arteries can restrict blood flow to the heart. One treatment is inserting a stent — a small ...

Home April 06, 2022
Home
News | Stents

November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in ...

Home November 09, 2021
Home
News | Stents

June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug ...

Home June 30, 2021
Home
News | Stents

April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...

Home April 14, 2021
Home
News | Stents

April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti ...

Home April 06, 2021
Home
News | Stents

December 21, 2020 – A proposed ASTM International standard will answer the need for a standardized test method that ...

Home December 21, 2020
Home
News | Stents

November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT ...

Home November 24, 2020
Home
Subscribe Now